The potency of TLR2 in HPV-associated cervical tumors has also been observed in the study of Zom et al. [33], who conjugated HPV16-encoded synthetic long peptides (SLPs) and the TLR2 ligand and registered that the conjugated SLPs were efficiently processed by antigen-presenting cells (APCs) and the immunological response was triggered. The gene discussed is TLR2; the disease is uterine cervix neoplasm.